

SIERRA LEONE

Support for Inactivated Polio Virus Vaccine

This Decision Letter sets out the Programme Terms of a Programme

1. Country:	Sierra Leone						
2. Vaccine grant number:	15-SLE-08h-Y, 1518-SLE-25c-X, 19-SLE-25c-X, 20-SLE-25b-X						
3. Date of Decision Letter:	9/30/2019						
4. Date of the Partnership Framework Agreement:	10 March 2013						
5. Programme title:	New Vaccine Support (NVS), Inactivated Polio Virus, Routine						
6. Vaccine type:	Inactivated Polio Virus						
7. Requested product presentation and formulation of vaccine:	Inactivated Polio Vaccine, 5 doses per vial, LIQUID						
8. Programme Duration:¹	2015-2020						
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2015-2019	2020	2021	2022	2023	2024	Total²
Programme Budget (US\$)	1,161,500	-	-	-	-	-	1,161,500
10. Vaccine introduction grant							
	Approval						
	Year	Grant Number	Amount (US\$)				
	2015	15-SLE-08h-Y	180,000				
	0	-	-				
	Disbursement						
	Disbursement date		Amount (US\$)				
	8 May 2015		180,000				
11. Product switch grant	Not applicable						
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)						
Type of supplies to be purchased with Gavi funds	2015-2019	2020	2021				

Number of vaccine doses		-	-												
Annual Amounts (US\$)	1,161,500	-	-												
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.														
14. Self-procurement:	Not applicable														
15. Co-financing obligations:	<p>Not applicable</p> <p>Gavi's usual co-financing requirements do not apply to IPV. However, the Country is encouraged to contribute to vaccine and/or supply costs for IPV.</p>														
16. Operational support for campaigns:	Not applicable														
17. Additional Reporting Requirements:	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</td> <td></td> </tr> <tr> <td> <ul style="list-style-type: none"> Vaccine stock levels including buffer stock </td> <td>31 March 2020</td> </tr> <tr> <td> <ul style="list-style-type: none"> Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received </td> <td>15 May 2020</td> </tr> <tr> <td> <ul style="list-style-type: none"> Country shall report the actual switch date in the first renewal request following the actual implementation </td> <td></td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>				Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year:		<ul style="list-style-type: none"> Vaccine stock levels including buffer stock 	31 March 2020	<ul style="list-style-type: none"> Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received 	15 May 2020	<ul style="list-style-type: none"> Country shall report the actual switch date in the first renewal request following the actual implementation 		In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
	Due dates														
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:															
<ul style="list-style-type: none"> Vaccine stock levels including buffer stock 	31 March 2020														
<ul style="list-style-type: none"> Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received 	15 May 2020														
<ul style="list-style-type: none"> Country shall report the actual switch date in the first renewal request following the actual implementation 															
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat														

18. Financial clarifications:	Not applicable
19. Other:	<p>Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.</p>

Signed by
On behalf of Gavi



Thabani Maphosa
Managing Director, Country Programmes
30 September 2019